The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer

[1]  J. Brooks,et al.  Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness , 2012, Oncogene.

[2]  J. Lindberg,et al.  Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer , 2012, Oncogene.

[3]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[4]  Arul M Chinnaiyan,et al.  Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. , 2011, Neoplasia.

[5]  Wei Li,et al.  Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. , 2011, Cancer research.

[6]  Peter C. Hollenhorst,et al.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. , 2011, Genes & development.

[7]  O. Kallioniemi,et al.  Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer , 2011, The EMBO journal.

[8]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[9]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[10]  Hongtao Yu,et al.  Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.

[11]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[12]  S. Dhanasekaran,et al.  Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.

[13]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[14]  C. Glass,et al.  Reprogramming Transcription via Distinct Classes of Enhancers Functionally Defined by eRNA , 2011, Nature.

[15]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[16]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[17]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[18]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[19]  K. Pienta,et al.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.

[20]  H. Timmers,et al.  Histone lysine methylation and demethylation pathways in cancer. , 2011, Biochimica et biophysica acta.

[21]  J. Lis,et al.  CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. , 2010, Genes & development.

[22]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[23]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[24]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[25]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[26]  Takahito Hara,et al.  Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[27]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[28]  S. Varambally,et al.  Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.

[29]  Francesca Demichelis,et al.  Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.

[30]  Andrew R. Gehrke,et al.  Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.

[31]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[32]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[33]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[34]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[35]  Mingming Jia,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..

[36]  Ryan D. Morin,et al.  Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.

[37]  A. Ashworth,et al.  CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. , 2009, Carcinogenesis.

[38]  B. Trask,et al.  Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. , 2009, Cancer research.

[39]  M. Rubin,et al.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.

[40]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[41]  Clifford A. Meyer,et al.  Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.

[42]  D. Olmos,et al.  Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. , 2009, Cancer research.

[43]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[44]  K. Ohashi,et al.  MST2- and Furry-Mediated Activation of NDR1 Kinase Is Critical for Precise Alignment of Mitotic Chromosomes , 2009, Current Biology.

[45]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[46]  M. Gerstein,et al.  Distinct genomic aberrations associated with ERG rearranged prostate cancer , 2009, Genes, chromosomes & cancer.

[47]  Bin Tean Teh,et al.  Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.

[48]  J. Stamatoyannopoulos,et al.  Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.

[49]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[50]  M. Dimopoulos,et al.  Somatic mutations of adenomatous polyposis coli gene and nuclear b‐catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication , 2009, International journal of cancer.

[51]  Emily H Turner,et al.  Targeted Capture and Massively Parallel Sequencing of Twelve Human Exomes , 2009, Nature.

[52]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[53]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[54]  F. Leisch,et al.  FlexMix Version 2: Finite Mixtures with Concomitant Variables and Varying and Constant Parameters , 2008 .

[55]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[56]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[57]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[58]  S. Serrano,et al.  KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations , 2008, Modern Pathology.

[59]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[60]  R. Shah,et al.  CHARACTERIZATION OF TMPRSS2-ETS GENE ABERRATIONS IN ANDROGEN INDEPENDENT METASTATIC PROSTATE CANCER , 2008 .

[61]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[62]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[63]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[64]  D. Turner,et al.  ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer , 2008, Expert review of anticancer therapy.

[65]  S. Varambally,et al.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.

[66]  H. Klocker,et al.  Plexin-B1 mutations in prostate cancer. , 2008, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[68]  Guy Cavet,et al.  Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.

[69]  S. Dhanasekaran,et al.  Integrative analysis of genomic aberrations associated with prostate cancer progression. , 2007, Cancer research.

[70]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[71]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[72]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[73]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[74]  J. Tchinda,et al.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. , 2007, Neoplasia.

[75]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[76]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[77]  Yi-jun Zhu,et al.  Identification of the MLL2 Complex as a Coactivator for Estrogen Receptor α* , 2006, Journal of Biological Chemistry.

[78]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[79]  Pengbo Liu,et al.  Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.

[80]  Jin-Tang Dong.  Prevalent mutations in prostate cancer , 2006, Journal of cellular biochemistry.

[81]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[82]  J. Mirosevich,et al.  Foxa1 and Foxa2 Interact with the Androgen Receptor to Regulate Prostate and Epididymal Genes Differentially , 2005, Annals of the New York Academy of Sciences.

[83]  Yutaka Miura,et al.  Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer , 2005, Nature Genetics.

[84]  Tony Pawson,et al.  Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer , 2004, Nature Genetics.

[85]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Paul Tempst,et al.  PINdb: a database of nuclear protein complexes from human and yeast , 2004, Bioinform..

[87]  W. Gerald,et al.  Gene expression profiling predicts clinical outcome of prostate cancer. , 2004, The Journal of clinical investigation.

[88]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[89]  Renjie Jin,et al.  The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. , 2003, Molecular endocrinology.

[90]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[91]  E. Latulippe,et al.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. , 2002, Cancer research.

[92]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[93]  S. Friedman,et al.  KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer , 2001, Science.

[94]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[95]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[96]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  A. Gronenborn,et al.  Correction of the NMR structure of the ETS1/DNA complex , 1997, Journal of biomolecular NMR.

[98]  K. Hamil,et al.  Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. , 1997, Molecular endocrinology.

[99]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.